Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bremelanotide Bridging Trial in Premenopausal Women with HSDD
NCT04943068Phase 3Completed
- Sponsor
- Kwang Dong Pharmaceutical Co., Ltd.
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoactive sexual desire disorder (HSDD) comparing Bremelanotide with Placebo (2 arms). Primary endpoint: Change from baseline to End of Study in the desire domain from the Female Sexual Function Index (FSFI) at 8 weeks. Started May 2021; status: completed.
02
Drugs
bremelanotide
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT04943068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943068.